HomeCompareHSTO vs RYLD

HSTO vs RYLD: Dividend Comparison 2026

HSTO yields 10000.00% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HSTO wins by $55137509079256512.00M in total portfolio value
10 years
HSTO
HSTO
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full HSTO calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — HSTO vs RYLD

📍 HSTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHSTORYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HSTO + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HSTO pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HSTO
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, HSTO beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HSTO + RYLD for your $10,000?

HSTO: 50%RYLD: 50%
100% RYLD50/50100% HSTO
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HSTO right now

HSTO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-29.6
Piotroski
1/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HSTO buys
0
RYLD buys
0
No recent congressional trades found for HSTO or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHSTORYLD
Forward yield10000.00%12.14%
Annual dividend / share$2.00$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$55137509079256512.00M$44.5K
Annual income after 10y$54,073,795,673,722,890,000,000.00$2,587.35
Total dividends collected$55066727460582336.00M$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HSTO vs RYLD ($10,000, DRIP)

YearHSTO PortfolioHSTO Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,914$1,213.65+$998.8KHSTO
2$95,539,393$94,457,943.93$14,099$1,351.30+$95.53MHSTO
3$8,447,007,736$8,344,780,585.66$16,580$1,494.55+$8446.99MHSTO
4$698,565,746,383$689,527,448,105.17$19,384$1,642.61+$698565.73MHSTO
5$54,040,711,670,213$53,293,246,321,583.74$22,535$1,794.70+$54040711.65MHSTO
6$3,910,851,616,519,516$3,853,028,055,032,387.00$26,063$1,950.00+$3910851616.49MHSTO
7$264,781,167,546,477,440$260,596,556,316,801,570.00$29,995$2,107.69+$264781167546.45MHSTO
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$34,361$2,266.99+$16772556223821.64MHSTO
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$39,194$2,427.12+$994124678068810.00MHSTO
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$44,525$2,587.35+$55137509079256512.00MHSTO

HSTO vs RYLD: Complete Analysis 2026

HSTOStock

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

Full HSTO Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this HSTO vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HSTO vs SCHDHSTO vs JEPIHSTO vs OHSTO vs KOHSTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.